Literature DB >> 2438954

Immunohistochemical evaluation of pleural mesothelioma and pulmonary adenocarcinoma. A bi-institutional study of 47 cases.

C N Otis, D Carter, S Cole, H Battifora.   

Abstract

Pleural mesotheliomas and peripheral pulmonary adenocarcinomas were evaluated by immunohistochemistry at two institutions (Yale University School of Medicine and the City of Hope National Medical Center). Twenty-three mesotheliomas, 11 with ultrastructural verification, and 24 pulmonary adenocarcinomas were studied. Antikeratin, anticarcinoembryonic antigen, anti-human milk fat globule related antigen, MC-1, B72.3, and Leu M-1 antibodies were employed. The immunohistochemistry of each case prepared at one institution was reviewed at the other. As groups, the two tumor types were distinguishable using this antibody panel. Essentially, mesotheliomas were keratin positive only. The adenocarcinomas were positive for CEA, MFG, B72.3, and Leu M-1. However, there were some ambiguities presented by the immunohistochemistry. The higher molecular weight keratins were found in most but not all mesotheliomas and in only a few adenocarcinomas. Lower molecular weight keratins were positive not only in all the mesotheliomas, but also in nearly all the adenocarcinomas, but also in a tumor determined by electron microscopy to be mesothelioma. Preabsorption of CEA decreased the sensitivity for adenocarcinoma, but did not change the positivity of the putative mesothelioma. B72.3 and Leu M-1 were specific for adenocarcinoma, but were found in only half of them. The MFG was apparently specific for adenocarcinoma, but the findings were difficult to interpret. At the level of individual cases, greater sensitivity of separation can be achieved by combining the results of two or more antibodies, but the lack of a detectable specific antigen in mesothelioma continues to make some cases difficult to evaluate by immunohistochemistry alone.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 2438954     DOI: 10.1097/00000478-198706000-00005

Source DB:  PubMed          Journal:  Am J Surg Pathol        ISSN: 0147-5185            Impact factor:   6.394


  12 in total

1.  Blood group antigens, Lewisx and Lewisy in the diagnostic discrimination of malignant mesothelioma versus adenocarcinoma.

Authors:  D Jordon; J Jagirdar; M Kaneko
Journal:  Am J Pathol       Date:  1989-11       Impact factor: 4.307

2.  Expression of CD15 in normal and metaplastic Paneth cells of the digestive tract.

Authors:  A Ariza; D López; E M Castellà; C Muñoz; M J Zújar; J L Mate
Journal:  J Clin Pathol       Date:  1996-06       Impact factor: 3.411

3.  Differences in lectin binding of malignant pleural mesothelioma and adenocarcinoma of the lung.

Authors:  T Kawai; S D Greenberg; L D Truong; C A Mattioli; M Klima; J L Titus
Journal:  Am J Pathol       Date:  1988-02       Impact factor: 4.307

4.  Mortality and cancer morbidity in cohorts of asbestos cement workers and referents.

Authors:  M Albin; K Jakobsson; R Attewell; L Johansson; H Welinder
Journal:  Br J Ind Med       Date:  1990-09

5.  Differentiation of adenocarcinoma of the lung from mesothelioma. Periodic acid-Schiff, monoclonal antibodies B72.3, and Leu M1.

Authors:  M L Warnock; A Stoloff; A Thor
Journal:  Am J Pathol       Date:  1988-10       Impact factor: 4.307

6.  Diagnostic tools for differentiating between pleural mesothelioma and lung adenocarcinoma in paraffin embedded tissue. Part I: Immunohistochemical findings.

Authors:  H Moch; M Oberholzer; P Dalquen; W Wegmann; F Gudat
Journal:  Virchows Arch A Pathol Anat Histopathol       Date:  1993

7.  Neu proto-oncogene amplification and expression in ovarian adenocarcinoma cell lines.

Authors:  B L King; D Carter; H G Foellmer; B M Kacinski
Journal:  Am J Pathol       Date:  1992-01       Impact factor: 4.307

8.  Malignant pleural mesothelioma in western Glasgow 1980-6.

Authors:  G Hulks; J S Thomas; E Waclawski
Journal:  Thorax       Date:  1989-06       Impact factor: 9.139

9.  ME1. A monoclonal antibody that distinguishes epithelial-type malignant mesothelioma from pulmonary adenocarcinoma and extrapulmonary malignancies.

Authors:  C J O'Hara; J M Corson; G S Pinkus; R A Stahel
Journal:  Am J Pathol       Date:  1990-02       Impact factor: 4.307

10.  Immunocytochemical characterization of malignant mesothelioma and carcinoma metastatic to the pleura: IOB3--a new tumor marker.

Authors:  C S Kortsik; P Werner; N Freudenberg; J C Virchow; C Kroegel; M Pott; H Matthys
Journal:  Lung       Date:  1995       Impact factor: 2.584

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.